


RECEIVED

OCT 25 2000

Attach #7

Page 1 of 1

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1530.0060004 TECH CENTER 1600/2900		APPLICATION NO. 09/557,907	
				APPLICANT Horton <i>et al.</i>			
				FILING DATE April 21, 2000		GROUP 1614	



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
<i>mm</i>	AB2	5,120,832	06/09/1992	Goeddel <i>et al.</i>	530	351	05/11/1990
<i>mm</i>	AC2	5,231,176	07/27/1993	Goeddel <i>et al.</i>	435	69.51	06/09/1992
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR		
	AS		
	AT		

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 5.14.02
-----------------------------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Attach #6

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1530.0060004	APPLICATION NO. 09/09/557,907
	APPLICANT HORTON <i>et al.</i>	
	FILING DATE April 21, 2000	GROUP 1614



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
mw	AA1	4,897,355	01/30/1990	Eppstein <i>et al.</i>	435	240.2	10/29/1987
	AB1	4,946,787	08/07/1990	Eppstein <i>et al.</i>	435	240.2	10/27/1989
	AC1	5,049,386	09/17/1991	Eppstein <i>et al.</i>	424	427	05/15/1990
	AD1	5,459,127	10/17/1995	Felgner <i>et al.</i>	514	7	09/16/1993
	AE1	5,578,475	11/26/1996	Jessee, J.A.	435	172.3	07/12/1994
	AF1	5,580,859	12/03/1996	Felgner <i>et al.</i>	514	44	03/18/1994
	AG1	5,589,466	12/31/1996	Felgner <i>et al.</i>	514	44	01/26/1995
	AH1	5,676,954	10/14/1997	Brigham, K.L.	424	450	05/08/1995
	AI1	5,693,622	12/02/1997	Wolff <i>et al.</i>	514	44	06/07/1995
	AJ1	5,641,665	06/24/1997	Hobart <i>et al.</i>	435	172.3	11/28/1994
mw	AK1	5,703,055	12/30/1997	Felgner <i>et al.</i>	514	44	01/26/1994

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
mw	AL1	EP 0 170 204	02/05/1986	Europe			Yes No
	AM1	WO 90/11092	10/04/1990	WIPO			Yes No
	AN1	WO 94/29469	12/22/1994	WIPO			Yes No
	AO1	WO 95/14381	06/01/1995	WIPO			Yes No
mw	AP1	WO 95/14651	06/01/1995	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
mw	AR	1	Adachi, T., <i>et al.</i> , "Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin," <i>Cancer Immunol. Immunother.</i> 37:1-6 (1993).
mw	AS	1	Adolf, G.R., "Monoclonal Antibodies and Enzyme Immunoassays Specific for Human Interferon (IFN) ω 1: Evidence that IFN- ω 1 Is a Component of Human Leukocyte IFN," <i>Virology</i> 175:410-417 (1990).
mw	AT	1	Adolf, G.R., <i>et al.</i> , "Human interferon ω 1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," <i>Biochim. Biophys. Acta</i> 1089:167-174 (1991).

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	10-15-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO.
1530.0060004

APPLICATION NO.
09/09/557, 900

APPLICANT
HORTON *et al.*

FILING DATE
April 21, 2000

GROUP
1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
WW	AA2	5,827,703	10/27/1998	Debs <i>et al.</i>	435	172.3	05/19/1994
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
WW	AL2	WO 95/17373	06/29/1995	WIPO			Yes No
	AM2	WO 96/18372	06/20/1996	WIPO			Yes No
	AN2	WO 96/26179	08/29/1996	WIPO			Yes No
	AO2	WO 96/40962	12/19/1996	WIPO			Yes No
WW	AP2	WO 96/40963	12/19/1996	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

WW	AR	2	Adolf, G.R., "Human interferon omega - a review," Multiple Sclerosis 1:S44-S47 (1995).
WW	AS	2	Almadrones, L., <i>et al.</i> , "Arterial, Peritoneal, and Intraventricular Access Devices," <i>Sem. Oncol. Nursing</i> 11:194-202 (1995).
WW	AT	2	Aihara, H., and Miyazaki, J.-I., "Gene transfer into muscle by electroporation in vivo," <i>Nature Biotechnol.</i> 16:867-870 (September 1998).

EXAMINER


DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
WU	AL3	WO 96/41873	12/27/1996	WIPO	—	—	Yes No
I	AM3	WO 97/00241	01/03/1997	WIPO	—	—	Yes No
	AN3	WO 97/00085	01/03/1997	WIPO	—	—	Yes No
↓	AO3	EP 0 465 529	4/29/1998	Europe	—	—	Yes No
MW	AP3	WO 99/64615	12/16/1999	WIPO	—	—	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

WU	AR	3	Baron, S., <i>et al.</i> , "The Interferons. Mechanisms of Action and Clinical Applications," <i>JAMA</i> 266:1375-1383 (1991).
MW	AS	3	Bast Jr., R.C., <i>et al.</i> , "Immunotherapy of a murine ovarian carcinoma with <i>Corynebacterium parvum</i> and specific heteroantiserum. I. Activation of Peritoneal Cells to Mediate Antibody-Dependent Cytotoxicity," <i>J. Immunol.</i> 123:1945-1951 (1979).
WU	AT	3	Belldegrun, A., <i>et al.</i> , "Human Renal Carcinoma Line Transfected With Interleukin-2 and/or Interferon α Gene(s): Implications for Live Cancer Vaccines," <i>J. Natl. Cancer Inst.</i> 85:207-216 (1993).

EXAMINER


DATE CONSIDERED

10-15-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

W	AR	4	Beller, U., <i>et al.</i> , "Phase IB Study of Low-Dose Intraperitoneal Recombinant Interleukin-2 in Patients with Refractory Advanced Ovarian Cancer: Rationale and Preliminary Report," <i>Gynecol. Oncol.</i> 34:407-412 (1989).
mw	AS	4	Benedetti Panici, P., <i>et al.</i> , "Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look," <i>Cancer Treatment Rev.</i> 16(Supplement A):123-127 (1989).
na	AT	4	Berek, J.S., <i>et al.</i> , "Immunotherapy with Biochemically Dissociated Fractions of <i>Propionibacterium acnes</i> in a Murine Ovarian Cancer Model," <i>Cancer Res.</i> 44:1871-1875 (1984).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO.
1530.0060004

APPLICATION NO.
09/09/557,907

APPLICANT
HORTON *et al.*

FILING DATE
April 21, 2000

GROUP
1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

aw	AR	5	Bramson, J., <i>et al.</i> , "Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric Cytokine: <i>In Vitro</i> and <i>In Vivo</i> Production of Biologically Active Interleukin-12," <i>Hum. Gene Ther.</i> 7:333-342 (February 1996).
aw	AS	5	Budker, V., <i>et al.</i> , "The efficient expression of intravascularly delivered DNA in rat muscle," <i>Gene Ther.</i> 5:272-276 (1998).
nw	AT	5	Capon, D.J., <i>et al.</i> , "Two Distinct Families of Human and Bovine Interferon- α Genes Are Coordinately Expressed and Encode Functional Polypeptides," <i>Mol. Cell. Biol.</i> 5:768-779 (1985).

EXAMINER

[Signature]


DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>6</u>	Chapman, P.B., <i>et al.</i> , "A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma," <i>Investig. New Drugs</i> 6:179-188 (1988).
	AS	<u>6</u>	Childers, J.M., <i>et al.</i> , "Laparoscopic Surgical Staging of Ovarian Cancer," <i>Gynecol. Oncol.</i> 59:25-33 (1995).
	AT	<u>6</u>	Clement, P.B., "Reactive Tumor-Like Lesions of the Peritoneum," <i>Am. J. Clin. Pathol.</i> 103:673-676 (1995).

EXAMINER


DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/537,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Z	Coll, J.-L., <i>et al.</i> , "Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/genciclovir and IL-2 treatments," <i>Gene Ther.</i> 4:1160-1166 (November 1997).
	AS	Z	Danko, I., <i>et al.</i> , "Pharmacological enhancement of <i>in vivo</i> foreign gene expression in muscle," <i>Gene Ther.</i> 1:114-121 (1994).
	AT	Z	Davis, H.L., <i>et al.</i> , "Direct Gene Transfer into Skeletal Muscle <i>In Vivo</i> : Factors Affecting Efficiency of Transfer and Stability of Expression," <i>Hum. Gene Ther.</i> 4:151-159 (1993).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

JUL 20 2000




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	8	Doh, S.G., <i>et al.</i> , "Spatial-temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA," <i>Gene Ther.</i> 4:648-663 (1997).
	AS	8	Dougherty, G.J., <i>et al.</i> , "Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth <i>in vivo</i> ," <i>Cancer Immunol. Immunother.</i> 38:339-345 (1994).
	AT	8	Edwards, R.P., <i>et al.</i> , "Comparison of Toxicity and Survival Following Intraperitoneal Recombinant Interleukin-2 for Persistent Ovarian Cancer After Platinum: Twenty-Four-Hour Versus 7-Day Infusion," <i>J. Clin. Oncol.</i> 15:3399-3407 (1997).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO.
1530.0060004

APPLICATION NO.
09/09/557,907

APPLICANT
HORTON *et al.*

FILING DATE
April 21, 2000

GROUP
1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Feinstein, S.I., <i>et al.</i> , "Family of Human α -Interferon-Like Sequences," <i>Mol. Cell. Biol.</i> 5:510-517 (1985).
	AS	2	Felgner, P.L., <i>et al.</i> , "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," <i>Proc. Natl. Acad. Sci. USA</i> 84:7413-7417 (1987).
	AT	2	Felgner, P.L., and Ringold, G.M., "Cationic liposome-mediated transfection," <i>Nature</i> 337:387-388 (1989).

EXAMINER


DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	10	Felgner, J.H., <i>et al.</i> , "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," <i>J. Biol. Chem.</i> 269:2550-2561 (1994).
	AS	10	Ferrantini, M., <i>et al.</i> , " α_1 -Interferon Gene Transfer into Metastatic Friend Leukemia Cells Abrogated Tumorigenicity in Immunocompetent Mice: Antitumor Therapy by Means of Interferon-producing Cells," <i>Cancer Res.</i> 53:1107-1112 (1993).
	AT	10	Ferrantini, M., <i>et al.</i> , "IFN- α 1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8 ⁺ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity. Comparative Studies with IFN- γ -Producing TS/A Cells," <i>J. Immunol.</i> 153:4604-4615 (1994).

EXAMINER


DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>rw</i>	AR	<u>11</u>	Fjeld, J.G., <i>et al.</i> , "Radio-immunotargeting in experimental animal models of intraperitoneal cancer," <i>Acta Obstet. Gynecol. Scand. Suppl.</i> 71:105-111 (1992).
<i>uw</i>	AS	<u>11</u>	Flores, I., <i>et al.</i> , "Human Interferon Omega (ω) Binds to the α/β Receptor," <i>J. Biol. Chem.</i> 266:19875-19877 (1991).
<i>rw</i>	AT	<u>11</u>	Forstner, R., <i>et al.</i> , "Ovarian Cancer Recurrence: Value of MR Imaging," <i>Radiology</i> 196:715-720 (1995).

EXAMINER


DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,607APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	12	Freedman, R.S., <i>et al.</i> , "Intraperitoneal Adoptive Immunotherapy of Ovarian Carcinoma with Tumor-Infiltrating Lymphocytes and Low-Dose Recombinant Interleukin-2: A Pilot Trial," <i>J. Immunother.</i> 16:198-210 (1994).
	AS	12	Friedman, R.M., "Pharmacology of interferons in humans," in: <i>Interferons: A Primer</i> , Academic Press, New York, pp. 104-115 (1981).
	AT	12	Galvani, D.W., and Cawley, J.C., eds., "Cytokine Therapy," Cambridge Univ. Press, pp. 114-115 (1992).

EXAMINER

DATE CONSIDERED 10.15.01


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

Page 13 of 38



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	13	Gough, N.M., <i>et al.</i> , "Structure and expression of the mRNA for murine granulocyte-macrophage colony stimulating factor," <i>EMBO J.</i> 4:645-653 (1985).
	AS	13	Gramzinski, R.A., <i>et al.</i> , "Immune Response to a Hepatitis B DNA Vaccine in Aotus Monkeys: A Comparison of Vaccine Formulation, Route, and Method of Administration," <i>Mol. Med.</i> 4:109-118 (1998).
	AT	13	Hamilton, T.C., "Ovarian Cancer, Part I: Biology," <i>Curr. Probl. Cancer</i> , pp. 3-57 (1992).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
 1530.0060004

APPLICATION NO.
 09/09/557,901


Page 14 of 18

JUL 20 2000

APPLICANT
 HORTON *et al.*

FILING DATE
 April 21, 2000

GROUP
 1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	14	Hartikka, J., <i>et al.</i> , "An Improved Plasmid DNA Expression Vector for Direct Injection into Skeletal Muscle," <i>Hum. Gene Ther.</i> 7:1205-1217 (June 1996).
	AS	14	Hauptmann, R., and Swetly, P., "A novel class of human type I interferons," <i>Nucl. Acids Res.</i> 13:4739-4749 (1985).
	AT	14	Huang, H., <i>et al.</i> , "Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy <i>in vivo</i> ," <i>Gene Ther.</i> 3:980-987 (November 1996).

EXAMINER


DATE CONSIDERED

10-15-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	15	Imakawa, K., <i>et al.</i> , "Interferon-like sequence of ovine trophoblast protein secreted by embryonic trophoblast," <i>Nature</i> 330:377-379 (1987).
	AS	15	Jones, G.J., and Itri, L.M., "Safety and Tolerance of Recombinant Interferon Alfa-2a (Roferon®-A) in Cancer Patients," <i>Cancer</i> 57:1709-1715 (1986).
	AT	15	Kaido, T., <i>et al.</i> , "IFN- α_1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice," <i>Int. J. Cancer</i> 60:221-229 (1995).


EXAMINER

DATE CONSIDERED 10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

KW	AR	16	Kariko, K., <i>et al.</i> , "Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA," <i>Biochim. Biophys. Acta</i> 1369:320-334 (1998).
MW	AS	16	Kashima, N., <i>et al.</i> , "Unique structure of murine interleukin-2 as deduced from cloned cDNAs," <i>Nature</i> 313:402-404 (1985).
MW	AT	16	Kataoka, A., <i>et al.</i> , "A Study on the Distribution of Metastases at Autopsy in 70 Patients with Ovarian Cancer," <i>Acta Obstet. Gynaecol. Jpn.</i> 46:337-344 (1994).

EXAMINER


DATE CONSIDERED

(0.15.01)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

UN	AR	17	Kichler, A., <i>et al.</i> , "Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles," <i>Gene Ther.</i> 5:855-860 (1998).
M	AS	17	Kigawa, J., <i>et al.</i> , "Retroperitoneal Lymphadenectomy, Including the Para-aortic Nodes in Patients with Stage III Ovarian Cancer," <i>Am. J. Clin. Oncol.</i> 17:230-233 (1994).
Mel	AT	17	Kikuchi, Y., <i>et al.</i> , "Effects of granulocyte-colony-stimulating factor and interleukin-2 on ascites formation and the survival time of nude mice bearing human ovarian cancer cells," <i>Cancer Immunol. Immunother.</i> 43:257-261 (1996).

EXAMINER

DATE CONSIDERED

10.15.01


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

Page 18 of 38



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	18	Knapp, R.C., and Berkowitz, R.S., "Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model," <i>Am. J. Obstet. Gynecol.</i> 128:782-786 (1977).
	AS	18	Kubeš, M., <i>et al.</i> , "Cross-Species Antiviral and Antiproliferative Activity of Human Interferon- ω ," <i>J. Interferon Res.</i> 14:57-59 (1994).
	AT	18	Labhasetwar, V., <i>et al.</i> , "A DNA Controlled-Release Coating for Gene Transfer: Transfection in Skeletal and Cardiac Muscle," <i>J. Pharma. Sci.</i> 87:1347-1350 (November 1998).

EXAMINER


DATE CONSIDERED

10-15-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	19	Lawson, C.M., <i>et al.</i> , "In Vivo Expression of an Interferon- α Gene by Intramuscular Injection of Naked DNA," <i>J. Interferon and Cytokine Res.</i> 17:255-261 (May 1997).
	AS	19	Levy, M.Y., <i>et al.</i> , "Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood," <i>Gene Ther.</i> 3:201-211 (1996).
	AT	19	Lissoni, P., <i>et al.</i> , "Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions," <i>Tumori</i> 78:118-120 (1992).

EXAMINER

DATE CONSIDERED 10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO.
1530.0060004

APPLICATION NO.
09/09/557,907

APPLICANT
HORTON *et al.*

FILING DATE
April 21, 2000

GROUP
1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	20	Lotze, M.T., <i>et al.</i> , "Intraperitoneal Administration of Interleukin-2 in Patients With Cancer," <i>Arch. Surg.</i> 121:1373-1379 (1986).
	AS	20	Manthorpe, M., <i>et al.</i> , "Gene Therapy by Intramuscular Injection of Plasmid DNA: Studies on Firefly Luciferase Gene Expression in Mice," <i>Hum. Gene Ther.</i> 4:419-431 (1993).
	AT	20	Markman, M., <i>et al.</i> , "Phase I Trial of Intraperitoneal Taxol: A Gynecologic Oncology Group Study," <i>J. Clin. Oncol.</i> 10:1485-1491 (1992).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004

APPLICATION NO.
09/09/557,907

APPLICANT
HORTON *et al.*

FILING DATE
April 21, 2000

GROUP
1614

JUL 20 2000




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	21	Mathiesen, I., "Electroporation of skeletal muscle enhances gene transfer <i>in vivo</i> ," <i>Gene Ther.</i> 6:508-514 (1999).
	AS	21	Mir, L.M., <i>et al.</i> , "Long term, high level <i>in vivo</i> gene expression after electric pulse-mediated gene transfer into skeletal muscle," <i>C.R. Acad. Sci. Paris</i> 321:893-899 (1998).
	AT	21	Mir, L.M., <i>et al.</i> , "High-efficiency gene transfer into skeletal muscle mediated by electric pulses," <i>Proc. Natl. Acad. Sci. USA</i> 96:4262-4267 (April 1999).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,903APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AR	<u>22</u>	Mumper, R.J., <i>et al.</i> , "Polyvinyl Derivatives as Novel Interactive Polymers for Controlled Gene Delivery to Muscle," <i>Pharma. Res.</i> 13:701-709 (1996).
	AS	<u>22</u>	Mumper, R.J., <i>et al.</i> , "Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle," <i>J. Controlled Release</i> 52:191-203 (1998).
	AT	<u>22</u>	Naumann, R.W., <i>et al.</i> , "The Groshong Catheter as an Intraperitoneal Access Device in the Treatment of Ovarian Cancer Patients," <i>Gynecol. Oncol.</i> 50:291-293 (1993).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004

APPLICATION NO.
09/09/557,907

APPLICANT
HORTON *et al.*

FILING DATE
April 21, 2000

GROUP
1614




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	23	Nieroda, C., <i>et al.</i> , "Interferon- ω Augments Major Histocompatibility and Human Tumor-Associated Antigen Expression," <i>Mol. Cell. Different.</i> 4:335-351 (1996).
	AS	23	Norman, J., <i>et al.</i> , "Adjuvants for Plasmid DNA Vaccines," from <i>Methods in Molecular Medicine</i> , vol. 29. <i>DNA Vaccines: Methods and Protocols</i> , D.B. Lowrie and R.G. Whalen, Humana Press Inc., Totowa, N.J. pp. 185-196 (1999).
	AT	23	Ogura, H., <i>et al.</i> , "Implantation of Genetically Manipulated Fibroblasts into Mice as Antitumor α -Interferon Therapy," <i>Cancer Res.</i> 50:5102-5106 (1990).

EXAMINER

DATE CONSIDERED 10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004

APPLICATION NO.
09/09/557,907

APPLICANT
HORTON *et al.*

FILING DATE
April 21, 2000

GROUP
1614




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>24</u>	Ottow, R.T., <i>et al.</i> , "Immunotherapy of Intraperitoneal Cancer with Interleukin 2 and Lymphokine-Activated Killer Cells Reduces Tumor Load and Prolongs Survival in Murine Models," <i>Cell. Immunol.</i> 104:366-376 (1987).
	AS	<u>24</u>	Parker, S.E., <i>et al.</i> , "Cancer Gene Therapy Using Plasmid DNA: Safety Evaluation in Rodents and Non-Human Primates," <i>Hum. Gene Ther.</i> 6:575-590 (1995).
	AT	<u>24</u>	Pestka, S., and Langer, J.A., "Interferons and their actions," <i>Ann. Rev. Biochem.</i> 56:727-777 (1987).


EXAMINER

DATE CONSIDERED 10-15-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	25	Porgador, A., <i>et al.</i> , "Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cell Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence Against Parental Metastatic Cells," <i>Cancer Res.</i> 52:3679-3686 (1992).
	AS	25	Qin, Y.-J., <i>et al.</i> , "Gene Suture - A Novel method for Intramuscular Gene Transfer and its Application in Hypertension Therapy," <i>Life Sciences</i> 65:2193-2203 (1999).
	AT	25	Quesada, J.R., <i>et al.</i> , "Treatment of Hairy Cell Leukemia With Recombinant α -Interferon," <i>Blood</i> 68:493-497 (1986).

EXAMINER

DATE CONSIDERED 10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

Page 26 of 38

JUL 20 2000

PATENT & TRADEMARK OFFICE




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	26	Rakhmievich, A.L., <i>et al.</i> , "Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12," <i>Hum. Gene Ther.</i> 8:1303-1311 (July 1997).
	AS	26	Raz, E., <i>et al.</i> , "Systemic immunological effects of cytokine genes injected into skeletal muscle," <i>Proc. Natl. Acad. Sci. USA</i> 90:4523-4527 (1993).
	AT	26	Raz, E., <i>et al.</i> , "Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery," <i>Lupus</i> 4:286-292 (1995).

EXAMINER

DATE CONSIDERED

10-15-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

JUL 20 2000

PATENT & TRADEMARK OFFICE




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	27	Rizzuto, G., <i>et al.</i> , "Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation," <i>Proc. Natl. Acad. Sci. USA</i> 96:6417-6422 (May 1999).
	AS	27	Ross, G., <i>et al.</i> , "Gene Therapy in the United States: A Five-Year Status Report," <i>Hum. Gene Ther.</i> 7:1781-1790 (September 1996).
	AT	27	Rubin, J., <i>et al.</i> , "Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7," <i>Gene Ther.</i> 4:419-425 (May 1997).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

JUL 20 2000




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	28	Saffran, D.C., <i>et al.</i> , "Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: Induction of CD8 ⁺ T-cell immunity," <i>Cancer Gene Ther.</i> 5:321-330 (September-October 1998).
	AS	28	San, H., <i>et al.</i> , "Safety and Short-term Toxicity of a Novel Cationic Lipid Formulation for Human Gene Therapy," <i>Hum. Gene Ther.</i> 4:781-788 (1993).
	AT	28	Santodonato, L., <i>et al.</i> , "Cure of Mice with Established Metastatic Friend Leukemia Cell Tumors by a Combined Therapy with Tumor Cells Expressing Both Interferon- α 1 and Herpes Simplex Thymidine Kinase Followed by Ganciclovir," <i>Hum. Gene Ther.</i> 7:1-10 (January 1996).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004


APPLICATION NO.
09/09/557,907

APPLICANT
HORTON *et al.*

FILING DATE
April 21, 2000

GROUP
1614

JUL 20 2000



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	29	Santodonato, L., <i>et al.</i> , "Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN- α and HSVtk: perspectives for the generation of cancer vaccines," <i>Gene Ther.</i> 4:1246-1255 (November 1997).
	AS	29	Smith, B.F., <i>et al.</i> , "Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen," <i>Gene Ther.</i> 5:865-868 (1998).
	AT	29	Son, K., "Cisplatin-based interferon γ gene therapy of murine ovarian carcinoma," <i>Cancer Gene Ther.</i> 4:391-396 (November-December 1997).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

Page 30 of 38

JUL 20 2000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

rw	AR	30	Sparano, J.A., <i>et al.</i> , "Phase II Trials of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Breast Carcinoma and Carcinoma of the Lung, Ovary, and Pancreas and Other Tumors," <i>J. Immunother.</i> 16:216-223 (1994).
dw	AS	30	Steis, R.G., <i>et al.</i> , "Intraperitoneal Lymphokine-Activated Killer-Cell and Interleukin-2 Therapy for Malignancies Limited to the Peritoneal Cavity," <i>J. Clin. Oncol.</i> 8:1618-1629 (1990).
mw	AT	30	Stewart, H.J., <i>et al.</i> , "Interferon sequence homology and receptor binding activity of ovine trophoblast antiluteolytic protein," <i>J. Endocr.</i> 115:R13-R15 (1987).


EXAMINER

DATE CONSIDERED 10.5.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	31	Stewart, J.A., <i>et al.</i> , "Phase I Trial of Intraperitoneal Recombinant Interleukin-2/Lymphokine-activated Killer Cells in Patients with Ovarian Cancer," <i>Cancer Res.</i> 50:6302-6310 (1990).
	AS	31	Stopeck, A.T., <i>et al.</i> , "Phase I Study of Direct Gene Transfer of an Allogeneic Histocompatibility Antigen, HLA-B7, in Patients With Metastatic Melanoma," <i>J. Clin. Oncol.</i> 15:341-349 (January 1997).
	AT	31	Sugaya, S., <i>et al.</i> , "Inhibition of Tumor Growth by Direct Intratumoral Gene Transfer of Herpes Simplex Virus Thymidine Kinase Gene with DNA-Liposome Complexes," <i>Hum. Gene Ther.</i> 7:223-230 (January 1996).

EXAMINER

DATE CONSIDERED 10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,901APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

JUL 20 2000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

uw	AR	32	Szala, S., <i>et al.</i> , "The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of <i>Escherichia coli</i> cytosine deaminase gene into growing melanoma tumors," <i>Gene Ther.</i> 3:1026-1031 (November 1996).
rw	AS	32	Thomason, D.B., and Booth, F.W., "Stable incorporation of a bacterial gene into adult rat skeletal muscle <i>in vivo</i> ," <i>Am J Physiol.</i> 258:C578-C581 (March 1990).
mw	AT	32	Tokui, M., <i>et al.</i> , "Intramuscular Injection of Expression Plasmid DNA Is an Effective Means of Long-Term Systemic Delivery of Interleukin-5," <i>Biochem. Biophys. Res. Comm.</i> 233:527-531 (April 1997).

EXAMINER


DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	33	Tone, Y., <i>et al.</i> , "Structure and chromosomal location of the mouse interleukin-12 p35 and p40 subunit genes," <i>Eur. J. Immunol.</i> 26:1222-1227 (June 1996).
	AS	33	Urba, W.J., <i>et al.</i> , "Intraperitoneal Lymphokine-Activated Killer Cell/Interleukin-2 Therapy in Patients With Intra-abdominal Cancer: Immunologic Considerations," <i>J. Natl. Cancer Inst.</i> 81:602-611 (1989).
	AT	33	Vanhaelen, C.P.J., and Fisher, R.I., "Requirements for Successful Immunotherapy and Chemoimmunotherapy of a Murine Model of Ovarian Cancer," <i>Cancer Res.</i> 41:980-983 (1981).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

JUL 20 2000




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>34</u>	Vitadello, M., <i>et al.</i> , "Gene Transfer in Regenerating Muscle," <i>Hum. Gene Ther.</i> 5:11-18 (1994).
	AS	<u>34</u>	Wells, D.J., "Improv'd gene transfer by direct plasmid injection asociated with regeneration in mouse skeletal muscle," <i>FEBS Letters</i> 332:179-182 (October 1993).
	AT	<u>34</u>	West, W.H., <i>et al.</i> , "Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer," <i>New Engl. J. Med.</i> 316:898-905 (1987).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

JUL 20 2000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

WJ	AR	35	Wheeler, C.J., <i>et al.</i> , "A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung," <i>Proc. Natl. Acad. Sci. USA</i> 93:11454-11459 (October 1996).
WJ	AS	35	Winnacker, <i>From Genes to Clones</i> , Weinheim, Germany, pg. 290-293 (1987).
WJ	AT	35	Wolff, J.A., <i>et al.</i> , "Conditions Affecting Direct Gene Transfer into Rodent Muscle <i>In Vivo</i> ," <i>BioTechniques</i> 11:474-485 (1991).

EXAMINER

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	36	Yagi, K., <i>et al.</i> , "Interferon- β endogenously produced by intratumoral injection of cationic liposome-encapsulated gene: cytotoxic effect on glioma transplanted into nude mouse brain," <i>Biochem. Mol. Biol. Intl.</i> 32:167-171 (1994).
	AS	36	Yankauckas, M.A., <i>et al.</i> , "Direct Intratumor Injections of IL-2 Plasmid DNA: An Effective Method for Immunotherapy," <i>J. Cell. Biochem. Suppl.</i> 21A:429, Abstr. C6-552 (1995).
	AT	36	Yeow, W.-S., <i>et al.</i> , "Antiviral Activities of Individual Murine IFN- α Subtypes In Vivo: Intramuscular Injection of IFN Expression Constructs Reduces Cytomegalovirus Replication," <i>J. Immunol.</i> 160:2932-2939 (March 1998).

EXAMINER


DATE CONSIDERED

10/15/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	37	Yu, D., <i>et al.</i> , "Liposome-mediated <i>in vivo</i> E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/ <i>neu</i> ," <i>Oncogene</i> 11:1383-1388 (1995).
	AS	37	Zhang, J.F., <i>et al.</i> , "Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression," <i>Cancer Gene Ther.</i> 3:31-38 (January-February 1996).
	AT	37	Zhang, J.-F., <i>et al.</i> , "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy," <i>Proc. Natl. Acad. Sci. USA</i> 93:4513-4518 (April 1996).

EXAMINER

DATE CONSIDERED

10-15-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1530.0060004APPLICATION NO.
09/09/557,907APPLICANT
HORTON *et al.*FILING DATE
April 21, 2000GROUP
1614

Page 38 of 38

JUL 20 2000

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

mw	AR	38	English language abstract of EP 0 170 204 (Document AL1), Derwent World Patent Index, WPI Accession No. 1986-036962/198606.
	AS	38	
	AT	38	

EXAMINER

Mia

DATE CONSIDERED

10.15.01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.